
zzso are among the most active agents in zzso breast zzso zzso demonstrated a different toxicity profile when compared to zzso We performed a phase zzso study of zzso high-dose zzso therapy for advanced breast zzso zzso patients who had a diagnosis of zzso breast cancer received treatment at the zzso Anderson Cancer Center between June 1986 and December zzso The patients received escalating doses of zzso until a maximum tolerated dose zzso defined as grade 3 or 4 zzso toxicity or infection, was zzso The starting dose of 25 zzso given by short intravenous infusion, was escalated by zzso in each zzso cohort if each patient in the previous cohort tolerated the initial course and 2 or fewer patients reached the zzso The median cumulative dose of zzso was 93 zzso zzso zzso and the maximum single dose was 39 zzso zzso was the dose limiting zzso The median duration of zzso count zzso or zzso zzso was zzso zzso Four patients zzso had infections that required zzso 3 patients zzso had cardiac zzso One patient zzso achieved a complete response, and 3 zzso had a partial response, with an overall response rate of zzso No apparent zzso relationship was observed in our zzso The zzso dosage recommended for phase II studies is 25 zzso every zzso zzso We conclude that high-dose zzso therapy for zzso breast cancer was relatively well tolerated but was not associated with a higher response rate than that of standard dose zzso 

